U

University of Oxford | Oxford Vaccine Centre - Oxford Vaccine Group

Research site
(Unclaimed)
Location
Oxford Vaccine Centre, CCVTM Churchill Hospital, Oxford, Oxfordshire, England
Site insights

Top conditions

Depressive Disorder (13 trials)

Depression (8 trials)

Syndrome (5 trials)

Mood Disorders (5 trials)

Non-alcoholic Fatty Liver Disease (4 trials)

Top treatments

Ruxolitinib
PF-04995274
Upadacitinib
Prucalopride
Citalopram
Apitegromab
Octreotide
REGN4018
Lamotrigine
IMC-F106C

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 97
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
Locations recently updated
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) a...

Enrolling
Myeloproliferative Neoplasms
Drug: INCA033989
Drug: Ruxolitinib

This Phase 3 trial (Study SRK-015-003) is being conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spina...

Active, not recruiting
Anti-myostatin
Neuromuscular Manifestations
Drug: Placebo
Drug: Apitegromab

This study will explore whether sleep in stroke survivors is improved with digital cognitive behavioural therapy for insomnia (Sleepio), in compariso...

Enrolling
Stroke
Behavioral: Digital Cognitive Behavioural Therapy for Insomnia

Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully describe...

Enrolling
Major Depressive Disorder
Treatment Resistant Depression
Other: No intervention (placebo)
Drug: Ketamine Hydrochloride

IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-a...

Enrolling
Select Advanced Solid Tumors
Drug: IMC-F106C and monoclonal antibodies and chemotherapy
Drug: IMC-F106C and chemotherapy

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxoliti...

Enrolling
ET (Essential Thrombocythemia)
Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
Drug: INCB057643
Drug: Ruxolitinib

The main purpose of this study is to:Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab t...

Enrolling
Recurrent Primary Peritoneal Cancer
Recurrent Ovarian Cancer
Drug: REGN4018
Drug: Sarilumab

Trial sponsors

University of Oxford logo

University of Oxford (59 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems